Corporate -

Alfasigma Secures Exclusive Rights from Innovative Molecules to Parenteral Adibelivir for Treatment of HSV Encephalitis, an Ultra-Rare Disease

January 13, 2026

Alfasigma S.p.A. (“Alfasigma”), a global pharmaceutical company, and Innovative Molecules GmbH (“Innovative Molecules”), a clinical-stage biotechnology company, today announced a strategic par...

Filgotinib Shows Positive Topline Results Across Full Spectrum of Axial Spondyloarthritis in OLINGUITO Phase 3 Study

July 28, 2025

Alfasigma S.p.A today announced positive topline results from the OLINGUITO Phase 3 clinical trial (NCT05785611; Eudra CT 2022-501354-10-01),[i] evaluating filgotinib (marketed as Jyseleca® in approv...

Alfasigma Reports Record Growth in First-Ever Financial Results; €1.87 billion Revenue Setting the Stage for Future Growth

March 28, 2025

Alfasigma S.p.A (“Alfasigma” or the “Company”), a global pharmaceutical company founded over 75 years ago in Italy, where it is headquartered, today announced its financial results for the fis...

Alfasigma announces the Completion of Marketing Authorisation Transfer for Jyseleca® in the European Union

August 29, 2024

• Following a positive opinion from the EMA, the transfer of marketing authorization of Jyseleca from Galapagos NV to Alfasigma S.p.A has been approved by the European Commission. • Alfasigma S....

M&A for growth, 20 years of M&A in Italy, the best deals of 2023

May 17, 2024

Alfasigma S.p.A has been selected as a finalist in the 20th edition of the M&A Awards: 20 Years of M&A in Italy, The Best Deals Of 2023, the initiative promoted by KPMG and Fineurop Soditic Spa, with ...

In Piazza con Marino - A tribute event to Marino

February 19, 2024

Fondazione Golinelli organizined, on Saturday, February 17, a special day to pay tribute to Marino Golinelli, philanthropist, entrepreneur, researcher and art lover...

Alfasigma completes transaction to acquire the Jyseleca® business from Galapagos for up to €170 million

February 1, 2024

Bologna, 31 January 2024, 22:01 CET – Alfasigma S.p.A. is pleased to announce the successful completion of the transaction to acquire the Jyseleca® (filgotinib) business from Galapagos NV (Euronext...

Alfasigma signs an agreement to acquire Jyseleca® business for up to €170 million from Galapagos following October letter of intent

January 2, 2024

Alfasigma S.p.A today announced that it has signed an agreement with Galapagos NV (Euronext & NASDAQ: GLPG) to acquire the Jyseleca® (filgotinib) business for up to €170 million....

Alfasigma completes acquisition of Intercept Pharmaceuticals, Inc.

November 8, 2023

Alfasigma S.p.A. (“Alfasigma”) and Intercept Pharmaceuticals, Inc. ( “Intercept”) announced today the completion of the acquisition of Intercept by Alfasigma through its wholly owned subsidiar...

Alfasigma S.p.A. successfully completes tender offer for all outstanding shares of common stock of Intercept Pharmaceuticals, Inc.

November 8, 2023

Bologna, Italy – November 8, 2023 — Alfasigma S.p.A. (“Alfasigma”) announced today that it has, through its wholly owned subsidiary Interstellar Acquisition Inc. (“Interstellar”), successf...